Published 2019
| Version v1
Publication
Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study
Creators
- Hui, Rina
- Pearson, Alex
- Cortés, Javier
- Campbell, Christine
- Poirot, Camille
- Azim, Hatem A
- Fumagalli, Debora
- Lambertini, Matteo
- Daly, Fergus
- Arahmani, Amal
- Pérez-Garcia, José
- Aftimos, Philippe
- Bedard, Phillipe L
- Xuereb, Laura
- Scheepers, Elsemieke D
- Vicente, Malou
- Goulioti, Theodora
- Loibl, Sibylle
- Loi, Sherene
- Pierrat, Marie-Jeanne
- Turner, Nicholas C
- Andre, Fabrice
- Curigliano, Giuseppe
Contributors
Others:
- Hui, Rina
- Pearson, Alex
- Cortés, Javier
- Campbell, Christine
- Poirot, Camille
- Azim, Hatem A
- Fumagalli, Debora
- Lambertini, Matteo
- Daly, Fergu
- Arahmani, Amal
- Pérez-Garcia, José
- Aftimos, Philippe
- Bedard, Phillipe L
- Xuereb, Laura
- Scheepers, Elsemieke D
- Vicente, Malou
- Goulioti, Theodora
- Loibl, Sibylle
- Loi, Sherene
- Pierrat, Marie-Jeanne
- Turner, Nicholas C
- Andre, Fabrice
- Curigliano, Giuseppe
Description
FGFR1 gene is amplified in 14% of HR+/ HER2- breast cancer patients. Efficacy and safety of lucitanib, an inhibitor of VEGFR1-3, FGFR1-3 and PDGFRα/β, were assessed.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/987964
- URN
- urn:oai:iris.unige.it:11567/987964
Origin repository
- Origin repository
- UNIGE